(Bloomberg Markets) -- If you work in finance, there’s a good chance Singapore is on the short list of places

As several state legislative sessions have concluded or are drawing to a close, some of the high-profile legislation enacted by state lawmakers is just taking effect.

Looking for deals? Check out our favorites below or head over to our running list

A high-stakes lawsuit over the future of a widely used abortion drug is likely heading to the US Supreme Court, set to determine the fate of abortion rights access across the country for a second time within two years. Three Republican-appointed judges on a federal appeals court have determined that the federal government did not follow proper procedures when it amended regulations for a commonly used medication abortion drug in 2016. But the restrictions will not immediately take effect. The panel partially upheld a ruling from a Donald Trump-appointed federal judge in Texas, whose sweeping decision earlier this year threatened to strip access to the drug altogether. Nothing in the ruling from a three-judge panel on 16 August will go into effect until the nation’s highest court weighs in. Wednesday’s ruling argues that the US Food and Drug Administration unlawfully expanded access to mifepristone, which was first approved by the federal government more than 20 years ago. Mifepristone was first approved by the FDA in 2000 and is approved for use up to 10 weeks of pregnancy. A vast majority of abortions occur within the first nine weeks of pregnancy. From 2019 through 2020, nearly 93 per cent of all abortions were performed before the 13th week, according to the US Centers for Disease Control and Prevention. The drug – part of a two-drug protocol for medication abortions, the most common form of abortion care in the US – is the subject of a lawsuit from a group of anti-abortion activists represented by right-wing Christian legal group Alliance Defending Freedom, which joined efforts to overturn Roe v Wade at the Supreme Court last year. In April, US District Judge Matthew Kacsmaryk – a former right-wing activist lawyer who was appointed to the federal judiciary by Mr Trump – issued a ruling to suspend the FDA’s approval, which was immediately challenged by abortion rights advocates, providers, major medical groups, drug manufacturers and President Joe Biden’s administration. An initial ruling at the US Court of Appeals for the Fifth Circuit blocked part of that decision but struck down policies for mail-in prescriptions and rules that expanded the drug’s approval for pregnancies up to 10 weeks. On 21 April, the Supreme Court blocked the lower courts’ rulings from taking effect while the case plays out, retaining the status quo while the legal case plays out. Following the Supreme Court’s conservative supermajority decision to revoke a constitutional right to abortion care in Dobbs v Jackson Women’s Health Organization, at least 15 states – mostly across the US South – have effectively banned most abortions and imposed criminal penalties against providers. Abortion rights advocates and providers have warned that eliminating or restricting access to mifepristone could drastically impact an already-fragile landscape for abortion care. A ruling that undermines the FDA’s drug approval process could also open the door for other activist-driven legal battles over other drugs wrapped up in political debates, potentially inviting other destabilising lawsuits to Covid-19 vaccines, contraception, HIV medication, gender-affirming care, and other life-saving drugs. Read More What is mifepristone? The widely used pill in the abortion rights battle at the Supreme Court Abortion rights advocates win major victory in Ohio as voters reject GOP plan to thwart ballot measure Texas women detailed agonising pregnancies after being denied abortions. The state blames doctors Some abortion drug restrictions upheld by in a case bound for Supreme Court Akram criticizes Pakistan Cricket Board for leaving Imran Khan out of Independence Day video Netanyahu voices support for Israel's military after his allies and son lambaste security officials

Lopez chose a black bodysuit with a matching cape and boots for the cover photo, using a chair as a prop to show off the outfit

Meta's Threads had a moment in which it seemed it would overtake Twitter in a

From the outside, Club Soda looks like any number of London liquor stores with row after row of

This year all four of Apple's iPhone models have USB-C charging ports and slightly different

Looking to fuel up your Netflix queue with some high-octane action? Whether you're a fan

Naomi Watts has admitted that going through menopause in her mid-thirties felt like “the end of her worth”. Watts, now 55, said she thought of menopause as “equating to the end” of her career, when she experienced it three years after her breakthrough performance in David Lynch’s 2001 psychological thriller Mulholland Drive. In an interview with Times Radio on Thursday, the two-time Oscar-nominated actor added that the lack of conversation around menopause – or the end of menstruation – “told me that you don’t matter anymore”. She continued: “So I kind of spent a lot of time spinning out and turning in on myself, feeling panicked about the end of my career, the end of my worth. If I can’t bring children into the world, my partner will probably leave me. What do I mean? Where’s my purpose?” Watts has been advocating for greater awareness and sensitivity around the subject, with the actor launching her own menopausal beauty brand Stripes last October. In the interview, she noted that, while women come together to discuss their periods, first kisses, or experiences with getting pregnant, the conversation around menopause has remained shrouded in secrecy and shame. However, Watts acknowledged that she wouldn’t have spoken about her own experiences when she was younger. Opening up about her decision to talk about going through early menopause publicly, she said: “Maybe it was just the right timing, maybe that the average age of menopause is 51. Maybe I just had to get past that milestone to actually admit that that was me. However, Watts added, her outlook has since changed because she “got on top of the education” and has a better understanding of it. “I’ve also got my friends,” she continued, underscoring the importance of having a community. “We can moan about it if we have to, laugh about it and share our experiences openly. “I think when the conversation is off the table, that’s the worst part of it,” Watts said. The Impossible actor has previously said that going through early menopause was “incredibly isolating”, with the NHS estimating that premature menopause – before the age of 40 – affects one per cent of women in the UK. The symptoms are the same as perimenopause, or the years of transition leading up to menopause. These usually include changes in the pattern and/or frequency of menstrual cycles, anxiety, mood changes, hot flushes, and hair loss or thinning. Read More ‘It was the most isolating experience’: Meet the women with early menopause Smoking causes 150 cancer cases every single day in UK, study finds Millions of women able to get contraceptive pills over the counter next year Smoking causes 150 cancer cases every single day in UK, study finds Millions of women able to get contraceptive pills over the counter next year Woman with cystic fibrosis had weeks to live – now she’s climbing mountains

When was the last time you backed up your hard drive? If it’s been more

Rivals Uber Technologies Inc., DoorDash Inc. and Grubhub Inc. joined forces in suing New York City to block